Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel

Cancer Invest. 1998;16(2):67-71. doi: 10.3109/07357909809039759.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II

MeSH terms

  • Adult
  • Breast Neoplasms / drug therapy*
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects*
  • Drug Administration Schedule
  • Heart / drug effects*
  • Heart Failure / chemically induced
  • Heart Failure / diagnosis
  • Humans
  • Middle Aged
  • Paclitaxel / administration & dosage
  • Paclitaxel / adverse effects*
  • Risk Factors
  • Stroke Volume

Substances

  • Doxorubicin
  • Paclitaxel